Sunday, 4 October 2026European Markets

ORKLA And OENEO Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - orkla (ork.ol) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
orkla (ork.ol) kr90.15 3.28% 13.66%
oeneo (sbt.pa) €10.30 3.24% 8.77%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. orkla (ork.ol)

3.28% forward dividend yield and 13.66% return on equity

orkla asa engages in branded consumer goods, and industrial and financial investment businesses. the company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. it also provides confectionery, biscuit, and snack products; and spices, masalas, and various food products based on dried mixes. in addition, the company offers personal care, hygiene, laundry detergent, and cleaning products; dietary supplement, oral care, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools and accessories; basic and wool garments; and professional cleaning products. it operates gymgrossisten, proteinfabrikken, bodystore, and fitnesstukku e-commerce portals for health and sports nutrition products; and restaurants. additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the nordic power market; and develops and sells real estate properties. it offers its food products under the grandiosa, toro, stabburet, felix, paulúns, fun light, abba, beauvais, kalles, den gamle fabrik, hamé, and vitana brands; confectionery and snacks under the kims, nidar, stratos, sætre, göteborgs kex, olw, panda, laima, selga, taffel, kalev, and nói síríus brands; home and personal care products under zalo, omo, blenda, jif, define, solidox, dr greve, lano, and bliw; health produtcs under möller's, jordan, vitalab, osl, cederroth first aid, salvequick, livol, nutrilett, maxim, collett, solidox and curamed brands; and food ingredients under the odense, mors hjemmebakte, kronjäst, bakkedal, and naturli brands. it has operations in norway, sweden, denmark, finland, iceland, the baltics, rest of europe, and internationally. the company was founded in 1918 and is headquartered in oslo, norway.

earnings per share

as for profitability, orkla has a trailing twelve months eps of kr6.08.

pe ratio

orkla has a trailing twelve months price to earnings ratio of 14.83. meaning, the purchaser of the share is investing kr14.83 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.66%.

volume

today's last reported volume for orkla is 195011 which is 84.89% below its average volume of 1291170.

volatility

orkla's last week, last month's, and last quarter's current intraday variation average was a negative 0.42%, a positive 0.21%, and a positive 0.90%.

orkla's highest amplitude of average volatility was 0.42% (last week), 0.98% (last month), and 0.90% (last quarter).

sales growth

orkla's sales growth is 4.5% for the present quarter and 2.2% for the next.

more news about orkla.

2. oeneo (sbt.pa)

3.24% forward dividend yield and 8.77% return on equity

oeneo sa operates in the wine industry worldwide. the company manufactures and sale of cork closures. it also provides products and solutions in wine making and spirits. oeneo sa is headquartered in bordeaux, france. oeneo sa operates as a subsidiary of caspar sas.

earnings per share

as for profitability, oeneo has a trailing twelve months eps of €0.52.

pe ratio

oeneo has a trailing twelve months price to earnings ratio of 19.81. meaning, the purchaser of the share is investing €19.81 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.77%.

volatility

oeneo's last week, last month's, and last quarter's current intraday variation average was a negative 0.75%, a negative 0.19%, and a positive 1.58%.

oeneo's highest amplitude of average volatility was 2.71% (last week), 1.49% (last month), and 1.58% (last quarter).

volume

today's last reported volume for oeneo is 142603 which is 1259.16% above its average volume of 10492.

revenue growth

year-on-year quarterly revenue growth declined by 13.5%, now sitting on 305.73m for the twelve trailing months.

moving average

oeneo's value is under its 50-day moving average of €11.03 and way under its 200-day moving average of €11.55.

more news about oeneo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com